JADRAN – GALENSKI LABORATORIJ d.d.

JADRAN – GALENSKI LABORATORIJ d.d. (abbreviated JGL d.d.) is a Croatian pharmaceutical company headquartered in Rijeka. Founded in 1991, it has grown into a regional player in generic medicines, over-the-counter products and medical devices, with a particular strength in eye-care preparations. The company operates through JGL Group and serves markets across Croatia, Bosnia and Herzegovina, Montenegro, North Macedonia, Serbia, Slovenia and Kosovo. Its product portfolio includes prescription and non-prescription medicines, with well-known brands such as Viset tetrahydrozoline eye drops for reducing eye redness. JGL is privately held, with a share capital of EUR 17,156,945 paid in full and 1,319,765 shares issued. The company is led by President of the Board of Directors Eva Usmiani Capobianco and Executive Director Alenka Jajac-Knez. JGL has pursued growth through acquisitions, including Medicuspharma in 2025, and has invested in sustainability-linked bonds and new production facilities. Its registered office is at Svilno 20, 51000 Rijeka, Croatia.

JADRAN – GALENSKI LABORATORIJ d.d. was founded in 1991 in Rijeka, Croatia. The company, commonly known as JGL, established itself as a pharmaceutical manufacturer with a focus on generic medicines and eye-care products. Over the decades, it expanded its presence across the Adriatic region and Southeast Europe, serving markets including Croatia, Bosnia and Herzegovina, Montenegro, North Macedonia, Serbia, Slovenia and Kosovo. JGL operates as a group, JGL Group, and has pursued strategic acquisitions to broaden its portfolio. In October 2025, JGL acquired Medicuspharma, expanding its portfolio of generic medicines in Croatia. The company has also invested in sustainability initiatives, issuing a sustainability-linked bond and reporting on its progress. In July 2025, JGL established a new company, MARIMED d.o.o. The company has reported record financial results and new investment plans, including its largest investment to date. JGL is privately held, with a share capital of EUR 17,156,945 paid in full and 1,319,765 shares issued. Its leadership includes President of the Board of Directors Eva Usmiani Capobianco and Executive Director Alenka Jajac-Knez. The company continues to develop and market a range of pharmaceutical products, including the Viset tetrahydrozoline eye drops for reducing eye redness.

• 2025

  Acquired Medicuspharma, expanding generic medicines portfolio in Croatia.

• 2025

  Established MARIMED d.o.o.

• 1991

  Company founded in Rijeka, Croatia.

Regional pharmaceutical company focused on generic medicines, eye care and medical devices for Adriatic and Southeast European markets.

• Viset

  Tetrahydrozoline eye drops for reducing eye redness and decongesting the mucosa of the eye.

1. 1Basic information - JGLjgl.eu
2. 2Corporate Documents - JGLjgl.eu
3. 3Product Portfolio - JGLjgl.eu
4. 4Viset - JGLjgl.eu
5. 5JADRAN – GALENSKI LABORATORIJ d.d. - Wikidatawikidata.org